Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merck & Co Inc (NYSE:MRK)

55.88
Delayed Data
As of Jun 24
 -1.80 / -3.12%
Today’s Change
45.69
Today|||52-Week Range
60.07
+5.79%
Year-to-Date
Can Gilead Sciences Rebound in the Second Half of 2016?
12:07pm / MotleyFool.com - Paid Partner Content
Dow 30 Stock Roundup: Microsoft Acquires LinkedIn, Merck to Buy Afferent Pharmaceutic...
Jun 17 / Zacks.com - Paid Partner Content
Why Investors Are Paying a Premium for These 3 Drugmakers
Jun 24 / MotleyFool.com - Paid Partner Content
Merck & Co., Inc. Wins This Round of the Immunotherapy Lung-Cancer Battle
Jun 16 / MotleyFool.com - Paid Partner Content
Sanofi's Likely Sweetener for Medivation Panned
Jun 23 / TheStreet.com - Paid Partner Content
Merck & Co. Inc. Shares Jump On Positive Lung Cancer Treatment Trial Results
Jun 16 / Zacks.com - Paid Partner Content
Incyte Reports Epacadostat Combination Study Initiation
Jun 23 / Zacks.com - Paid Partner Content
Merck's Biosimilar Version of Lantus Tops Phase III Studies
Jun 14 / Zacks.com - Paid Partner Content
Zika vaccine maker's stock is on fire
Jun 22 / CNNMoney.com
Should Pfizer Buy This Beaten-Down Immuno-Oncology Company?
Jun 14 / MotleyFool.com - Paid Partner Content
Stock Market News for June 20, 2016
Jun 20 / Zacks.com - Paid Partner Content
5 Things Organovo Holdings, Inc. Management Wants You to Know
Jun 13 / MotleyFool.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Baker Hughes, LinkedIn, Microsoft, Apple and Merck
Jun 20 / Zacks.com - Paid Partner Content
Tricking the Common Cold Into Destroying Cancer
Jun 13 / MotleyFool.com - Paid Partner Content
Gilead Sciences: Where's the Value?
Jun 19 / MotleyFool.com - Paid Partner Content
Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
Jun 13 / Zacks.com - Paid Partner Content
3 Top Big Pharma Stocks to Buy Now
Jun 19 / MotleyFool.com - Paid Partner Content
President raises patient and business hope for cancer treatment
Jun 02 / FT.com - Paid Partner Content
3 Reasons Gilead Sciences Is a Buy
Jun 17 / MotleyFool.com - Paid Partner Content
Cancer doctors face next drug challenge
Jun 01 / FT.com - Paid Partner Content
Wall Street heads for second straight weekly loss
Jun 17 / FT.com - Paid Partner Content